Pharma major Dr. Reddy’s Laboratories has launched over-the-counter Nicotine Polacrilex lozenges in the U.S. market.
The Nicotine lozenges brands and store brand markets had U.S. retail sales of around $200 million for the most recent 52 weeks ended May 17, 2020, the company said citing market research company IRI figures.
The OTC Nicotine Polacrilex lozenges, 2mg and 4mg, launched by the company are the store brand version of Nicorette lozenges. Nicorette is a trademark of GlaxoSmithKline Consumer Healthcare L.P.
CEO of North America Generics Marc Kikuchi said the launch of the product “represents our continuing commitment to the OTC category of Smoking Cessation. The launch demonstrates our ability to deliver on more complex dosage forms for the benefit of consumers who wish to quit smoking by reducing withdrawal symptoms, including nicotine cravings.”
Nicotine Polacrilex Lozenges are an important addition to the company’s current offering of Nicotine Replacement Therapy, including Nicotine Transdermal System Patches, sold as Habitrol brand and various store brands, he said in a release.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath